{
 "disease": "chronic-myeloid-leukemia",
 "label": "Chronic myeloid leukemia",
 "url": "https://usebiotransfer.org/disease/chronic-myeloid-leukemia/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "dfab6b11819e",
  "targets": "49244a4cea4c"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "ABL1",
   "ensembl": "ENSG00000097007",
   "n_drug_entries": 27,
   "n_distinct_drugs": 21,
   "drugs": {
    "ASCIMINIB": "APPROVAL",
    "AT-9283": "PHASE_3",
    "AZD-0424": "PHASE_1",
    "BAFETINIB": "PHASE_2",
    "BOSUTINIB": "APPROVAL",
    "DASATINIB": "APPROVAL",
    "FLUMATINIB": "PHASE_3",
    "IMATINIB": "APPROVAL",
    "KW-2449": "PHASE_1",
    "NILOTINIB": "APPROVAL",
    "NILOTINIB HYDROCHLORIDE": "APPROVAL",
    "OLVEREMBATINIB": "PHASE_3",
    "PONATINIB": "APPROVAL",
    "RADOTINIB": "PHASE_3",
    "REBASTINIB": "PHASE_1_2",
    "REGORAFENIB": "APPROVAL",
    "RUSERONTINIB": "PHASE_3",
    "SARACATINIB": "PHASE_2_3",
    "UMBRALISIB": "APPROVAL",
    "VODOBATINIB": "PHASE_2",
    "XL-228": "PHASE_1"
   },
   "approved": [
    "ASCIMINIB",
    "BOSUTINIB",
    "DASATINIB",
    "IMATINIB",
    "NILOTINIB",
    "NILOTINIB HYDROCHLORIDE",
    "PONATINIB",
    "REGORAFENIB",
    "UMBRALISIB"
   ],
   "n_approved": 9,
   "approved_for": {
    "ASCIMINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "BOSUTINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "myeloid leukemia",
     "breast cancer"
    ],
    "DASATINIB": [
     "acute lymphoblastic leukemia",
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "lymphoid leukemia"
    ],
    "IMATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "hypereosinophilic syndrome",
     "myelodysplastic/myeloproliferative disease",
     "dermatofibrosarcoma protuberans",
     "gastrointestinal stromal tumor",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "B-cell acute lymphoblastic leukemia"
    ],
    "NILOTINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "NILOTINIB HYDROCHLORIDE": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "PONATINIB": [
     "lymphoid leukemia",
     "myeloid leukemia",
     "acute lymphoblastic leukemia",
     "chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "UMBRALISIB": [
     "follicular lymphoma",
     "marginal zone lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "BCR",
   "ensembl": "ENSG00000186716",
   "n_drug_entries": 15,
   "n_distinct_drugs": 10,
   "drugs": {
    "ASCIMINIB": "APPROVAL",
    "BOSUTINIB": "APPROVAL",
    "DASATINIB": "APPROVAL",
    "IMATINIB": "APPROVAL",
    "NILOTINIB": "APPROVAL",
    "NILOTINIB HYDROCHLORIDE": "APPROVAL",
    "OLVEREMBATINIB": "PHASE_3",
    "PONATINIB": "APPROVAL",
    "RADOTINIB": "PHASE_3",
    "VODOBATINIB": "PHASE_2"
   },
   "approved": [
    "ASCIMINIB",
    "BOSUTINIB",
    "DASATINIB",
    "IMATINIB",
    "NILOTINIB",
    "NILOTINIB HYDROCHLORIDE",
    "PONATINIB"
   ],
   "n_approved": 7,
   "approved_for": {
    "ASCIMINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "BOSUTINIB": [
     "breast cancer",
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "myeloid leukemia"
    ],
    "DASATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "acute lymphoblastic leukemia",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "lymphoid leukemia"
    ],
    "IMATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "myelodysplastic/myeloproliferative disease",
     "gastrointestinal stromal tumor",
     "dermatofibrosarcoma protuberans",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "B-cell acute lymphoblastic leukemia",
     "hypereosinophilic syndrome"
    ],
    "NILOTINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "NILOTINIB HYDROCHLORIDE": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "PONATINIB": [
     "lymphoid leukemia",
     "myeloid leukemia",
     "acute lymphoblastic leukemia",
     "chronic myelogenous leukemia, BCR-ABL1 positive"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "LYN",
   "ensembl": "ENSG00000254087",
   "n_drug_entries": 9,
   "n_distinct_drugs": 9,
   "drugs": {
    "BAFETINIB": "PHASE_2",
    "BOSUTINIB": "APPROVAL",
    "DASATINIB": "APPROVAL",
    "ENMD-981693": "PHASE_2",
    "ILORASERTIB": "PHASE_2",
    "JNJ-26483327": "PHASE_1",
    "TG100-801": "PHASE_2",
    "TOLIMIDONE": "PHASE_2",
    "XL-228": "PHASE_1"
   },
   "approved": [
    "BOSUTINIB",
    "DASATINIB"
   ],
   "n_approved": 2,
   "approved_for": {
    "BOSUTINIB": [
     "breast cancer"
    ],
    "DASATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "acute lymphoblastic leukemia",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "lymphoid leukemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "SRC",
   "ensembl": "ENSG00000197122",
   "n_drug_entries": 11,
   "n_distinct_drugs": 11,
   "drugs": {
    "AZD-0424": "PHASE_1",
    "BOSUTINIB": "APPROVAL",
    "DASATINIB": "APPROVAL",
    "ENMD-981693": "PHASE_2",
    "ILORASERTIB": "PHASE_2",
    "JNJ-26483327": "PHASE_1",
    "SARACATINIB": "PHASE_2_3",
    "TG100-801": "PHASE_2",
    "TIRBANIBULIN": "APPROVAL",
    "VANDETANIB": "APPROVAL",
    "XL-228": "PHASE_1"
   },
   "approved": [
    "BOSUTINIB",
    "DASATINIB",
    "TIRBANIBULIN",
    "VANDETANIB"
   ],
   "n_approved": 4,
   "approved_for": {
    "BOSUTINIB": [
     "breast cancer"
    ],
    "DASATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "acute lymphoblastic leukemia",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "lymphoid leukemia"
    ],
    "TIRBANIBULIN": [
     "actinic keratosis"
    ],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "ASXL1",
   "ensembl": "ENSG00000171456",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "RUNX1",
   "ensembl": "ENSG00000159216",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "IKZF1",
   "ensembl": "ENSG00000185811",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "BCL2",
   "ensembl": "ENSG00000171791",
   "n_drug_entries": 7,
   "n_distinct_drugs": 5,
   "drugs": {
    "APG-2575": "PHASE_3",
    "NAVITOCLAX": "APPROVAL",
    "OBATOCLAX": "PHASE_3",
    "OBLIMERSEN": "APPROVAL",
    "VENETOCLAX": "APPROVAL"
   },
   "approved": [
    "NAVITOCLAX",
    "OBLIMERSEN",
    "VENETOCLAX"
   ],
   "n_approved": 3,
   "approved_for": {
    "NAVITOCLAX": [],
    "OBLIMERSEN": [],
    "VENETOCLAX": [
     "B-cell chronic lymphocytic leukemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "STAT5A",
   "ensembl": "ENSG00000126561",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "JAK2",
   "ensembl": "ENSG00000096968",
   "n_drug_entries": 31,
   "n_distinct_drugs": 26,
   "drugs": {
    "AC-430": "PHASE_1",
    "AT-9283": "PHASE_3",
    "AZD-1480": "PHASE_2",
    "BARICITINIB": "APPROVAL",
    "BMS-911543": "PHASE_2",
    "CT-1578": "PHASE_1",
    "DELGOCITINIB": "APPROVAL",
    "DEURUXOLITINIB": "APPROVAL",
    "FEDRATINIB": "APPROVAL",
    "FILGOTINIB": "APPROVAL",
    "GANDOTINIB": "PHASE_2",
    "GUSACITINIB": "PHASE_2",
    "IZENCITINIB": "PHASE_2_3",
    "LESTAURTINIB": "APPROVAL",
    "MOMELOTINIB": "APPROVAL",
    "MOMELOTINIB DIHYDROCHLORIDE": "APPROVAL",
    "NEZULCITINIB": "PHASE_2",
    "NS-018": "PHASE_2",
    "PACRITINIB": "APPROVAL",
    "PEFICITINIB": "PHASE_3",
    "RUXOLITINIB": "APPROVAL",
    "TOFACITINIB": "APPROVAL",
    "UPADACITINIB": "APPROVAL",
    "UPADACITINIB HEMIHYDRATE": "APPROVAL",
    "XL-019": "PHASE_3",
    "ZOTIRACICLIB": "PHASE_1_2"
   },
   "approved": [
    "BARICITINIB",
    "DELGOCITINIB",
    "DEURUXOLITINIB",
    "FEDRATINIB",
    "FILGOTINIB",
    "LESTAURTINIB",
    "MOMELOTINIB",
    "MOMELOTINIB DIHYDROCHLORIDE",
    "PACRITINIB",
    "RUXOLITINIB",
    "TOFACITINIB",
    "UPADACITINIB",
    "UPADACITINIB HEMIHYDRATE"
   ],
   "n_approved": 13,
   "approved_for": {
    "BARICITINIB": [
     "juvenile idiopathic arthritis",
     "atopic eczema",
     "rheumatoid arthritis",
     "juvenile dermatomyositis"
    ],
    "DELGOCITINIB": [
     "atopic eczema",
     "Eczematoid dermatitis",
     "dermatitis"
    ],
    "DEURUXOLITINIB": [
     "alopecia areata"
    ],
    "FEDRATINIB": [
     "myeloproliferative disorder",
     "primary myelofibrosis",
     "myelofibrosis",
     "acquired polycythemia vera"
    ],
    "FILGOTINIB": [
     "rheumatoid arthritis"
    ],
    "LESTAURTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "MOMELOTINIB": [
     "myelofibrosis"
    ],
    "MOMELOTINIB DIHYDROCHLORIDE": [
     "myelofibrosis",
     "Splenomegaly",
     "myeloproliferative disorder"
    ],
    "PACRITINIB": [
     "myelofibrosis",
     "primary myelofibrosis",
     "acquired polycythemia vera"
    ],
    "RUXOLITINIB": [
     "essential thrombocythemia",
     "myelofibrosis",
     "Eczematoid dermatitis",
     "myeloproliferative disorder",
     "graft versus host disease",
     "acquired polycythemia vera",
     "chronic graft versus host disease",
     "vitiligo",
     "primary myelofibrosis"
    ],
    "TOFACITINIB": [
     "psoriatic arthritis",
     "rheumatoid arthritis"
    ],
    "UPADACITINIB": [
     "rheumatoid arthritis",
     "atopic eczema",
     "ulcerative colitis",
     "Crohn disease",
     "psoriatic arthritis",
     "temporal arteritis",
     "ankylosing spondylitis"
    ],
    "UPADACITINIB HEMIHYDRATE": [
     "rheumatoid arthritis",
     "ulcerative colitis"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "ABCB1",
   "ensembl": "ENSG00000085563",
   "n_drug_entries": 5,
   "n_distinct_drugs": 5,
   "drugs": {
    "BIRICODAR": "PHASE_2",
    "ENCEQUIDAR": "PHASE_3",
    "TARIQUIDAR": "PHASE_3",
    "VALSPODAR": "PHASE_3",
    "ZOSUQUIDAR": "PHASE_1_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "BCR-ABL1": {
    "n": 463,
    "n_observational": 117,
    "n_active": 54,
    "n_withdrawn": 15,
    "trials": [
     {
      "nct": "NCT01746836",
      "title": "Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03263572",
      "title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03459534",
      "title": "A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03595917",
      "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",
      "status": "RECRUITING",
      "last_update": "2025-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03934372",
      "title": "Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04838041",
      "title": "Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04877522",
      "title": "Asciminib Roll-over Study",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04925479",
      "title": "Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05304377",
      "title": "A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05367700",
      "title": "A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.",
      "status": "RECRUITING",
      "last_update": "2023-01-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06163430",
      "title": "A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)",
      "status": "RECRUITING",
      "last_update": "2026-01-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06236724",
      "title": "Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06368414",
      "title": "A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06401603",
      "title": "A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06409936",
      "title": "PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML",
      "status": "RECRUITING",
      "last_update": "2025-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06423911",
      "title": "Study of Olverembatinib (HQP1351) in Patients With CP-CML",
      "status": "RECRUITING",
      "last_update": "2025-06-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06514534",
      "title": "Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.",
      "status": "RECRUITING",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06629584",
      "title": "Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06757855",
      "title": "Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML",
      "status": "RECRUITING",
      "last_update": "2025-05-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06787144",
      "title": "ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants",
      "status": "RECRUITING",
      "last_update": "2025-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06817720",
      "title": "Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07269470",
      "title": "Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07354074",
      "title": "Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002598",
      "title": "Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002681",
      "title": "Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2011-06-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002718",
      "title": "T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia",
      "status": "COMPLETED",
      "last_update": "2015-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002746",
      "title": "Interleukin-2 in Treating Patients With Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2019-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002761",
      "title": "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2012-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002766",
      "title": "Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002771",
      "title": "Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-08-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002869",
      "title": "Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003694",
      "title": "Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2013-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004052",
      "title": "Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004245",
      "title": "Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004932",
      "title": "STI571 in Treating Patients With Recurrent Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004933",
      "title": "Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa",
      "status": "TERMINATED",
      "last_update": "2016-07-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005622",
      "title": "Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders",
      "status": "COMPLETED",
      "last_update": "2012-10-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005797",
      "title": "Bone Marrow Transplant in Treating Patients With Hematologic Cancers",
      "status": "COMPLETED",
      "last_update": "2020-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005823",
      "title": "Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2013-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005863",
      "title": "Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006040",
      "title": "Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006052",
      "title": "STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006053",
      "title": "STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa",
      "status": "COMPLETED",
      "last_update": "2013-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006091",
      "title": "Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment",
      "status": "WITHDRAWN",
      "last_update": "2018-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006092",
      "title": "Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia",
      "status": "TERMINATED",
      "last_update": "2012-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006343",
      "title": "STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006475",
      "title": "STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis",
      "status": "COMPLETED",
      "last_update": "2013-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00008164",
      "title": "Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia",
      "status": "UNKNOWN",
      "last_update": "2013-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00008307",
      "title": "Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders",
      "status": "UNKNOWN",
      "last_update": "2014-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00012259",
      "title": "Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00014469",
      "title": "Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00014495",
      "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer",
      "status": "COMPLETED",
      "last_update": "2016-01-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00015834",
      "title": "STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00015847",
      "title": "Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00015860",
      "title": "STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019656",
      "title": "Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020111",
      "title": "Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-04-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020969",
      "title": "Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes",
      "status": "TERMINATED",
      "last_update": "2020-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022048",
      "title": "Bevacizumab in Treating Patients With Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2013-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022451",
      "title": "Tipifarnib in Treating Young Patients With Refractory Leukemia",
      "status": "COMPLETED",
      "last_update": "2012-03-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022490",
      "title": "Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2016-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00023881",
      "title": "Bortezomib in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2018-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025402",
      "title": "Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025415",
      "title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction",
      "status": "COMPLETED",
      "last_update": "2013-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00027560",
      "title": "Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00028847",
      "title": "Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-09-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00030108",
      "title": "Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy",
      "status": "COMPLETED",
      "last_update": "2012-03-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00030303",
      "title": "Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00030550",
      "title": "Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2013-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00036712",
      "title": "Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation",
      "status": "UNKNOWN",
      "last_update": "2013-09-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00036738",
      "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "COMPLETED",
      "last_update": "2020-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00038675",
      "title": "Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2022-01-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00039416",
      "title": "Imatinib Mesylate in Treating Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2014-02-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00041990",
      "title": "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)",
      "status": "COMPLETED",
      "last_update": "2007-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00042003",
      "title": "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)",
      "status": "COMPLETED",
      "last_update": "2024-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00042016",
      "title": "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)",
      "status": "COMPLETED",
      "last_update": "2009-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00042822",
      "title": "FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2011-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00043134",
      "title": "Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome",
      "status": "UNKNOWN",
      "last_update": "2010-04-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00045006",
      "title": "Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2013-05-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00045305",
      "title": "Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes",
      "status": "COMPLETED",
      "last_update": "2023-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00045422",
      "title": "Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00047268",
      "title": "Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome",
      "status": "UNKNOWN",
      "last_update": "2013-09-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00047502",
      "title": "Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-11-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049686",
      "title": "VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2013-07-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00050531",
      "title": "High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2016-05-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00053001",
      "title": "Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2013-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00053157",
      "title": "Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia",
      "status": "COMPLETED",
      "last_update": "2022-10-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00053196",
      "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00053248",
      "title": "Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2012-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054431",
      "title": "Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00055874",
      "title": "Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-05-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060021",
      "title": "Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00062231",
      "title": "Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer",
      "status": "TERMINATED",
      "last_update": "2012-09-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00064090",
      "title": "3-AP and Cytarabine in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-07-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00064233",
      "title": "BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00064285",
      "title": "Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2010-05-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00064311",
      "title": "Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2012-03-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00066326",
      "title": "Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00066599",
      "title": "Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2013-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00068276",
      "title": "Cholecalciferol in Treating Patients With Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2018-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070499",
      "title": "Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00072579",
      "title": "Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment",
      "status": "COMPLETED",
      "last_update": "2017-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073944",
      "title": "BCX-1777 in Treating Patients With Refractory Cancer",
      "status": "COMPLETED",
      "last_update": "2013-05-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00081926",
      "title": "Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2009-11-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00083187",
      "title": "VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia",
      "status": "COMPLETED",
      "last_update": "2013-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00085449",
      "title": "Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",
      "status": "WITHDRAWN",
      "last_update": "2019-11-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088231",
      "title": "PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP",
      "status": "COMPLETED",
      "last_update": "2012-01-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00093639",
      "title": "Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2013-05-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00100997",
      "title": "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2013-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101595",
      "title": "Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101647",
      "title": "Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101660",
      "title": "Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib",
      "status": "COMPLETED",
      "last_update": "2012-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101816",
      "title": "Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2010-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00103701",
      "title": "BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00103844",
      "title": "Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00104975",
      "title": "Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-12-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00109707",
      "title": "A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110045",
      "title": "Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2012-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110058",
      "title": "Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00112775",
      "title": "BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate",
      "status": "UNKNOWN",
      "last_update": "2011-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00114257",
      "title": "Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders",
      "status": "COMPLETED",
      "last_update": "2013-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00114959",
      "title": "Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2015-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00123474",
      "title": "Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML",
      "status": "COMPLETED",
      "last_update": "2016-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00123487",
      "title": "Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML",
      "status": "COMPLETED",
      "last_update": "2014-11-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00124748",
      "title": "Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)",
      "status": "TERMINATED",
      "last_update": "2012-02-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00129740",
      "title": "Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2019-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00146913",
      "title": "AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year",
      "status": "UNKNOWN",
      "last_update": "2007-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171249",
      "title": "An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171899",
      "title": "Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2017-02-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171912",
      "title": "Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes",
      "status": "COMPLETED",
      "last_update": "2017-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00199186",
      "title": "Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "UNKNOWN",
      "last_update": "2007-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00210119",
      "title": "Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response",
      "status": "TERMINATED",
      "last_update": "2021-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00219726",
      "title": "Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2012-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00237120",
      "title": "Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)",
      "status": "COMPLETED",
      "last_update": "2009-11-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244829",
      "title": "Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00245037",
      "title": "Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00254423",
      "title": "Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00255346",
      "title": "Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)",
      "status": "COMPLETED",
      "last_update": "2025-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00255684",
      "title": "Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2016-11-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00258271",
      "title": "Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00261846",
      "title": "Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias",
      "status": "COMPLETED",
      "last_update": "2017-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00264160",
      "title": "Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy",
      "status": "COMPLETED",
      "last_update": "2017-03-06",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00267085",
      "title": "Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease",
      "status": "COMPLETED",
      "last_update": "2012-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00281879",
      "title": "Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2017-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00293384",
      "title": "Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2016-03-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295997",
      "title": "Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia",
      "status": "UNKNOWN",
      "last_update": "2014-01-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00297570",
      "title": "Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy",
      "status": "UNKNOWN",
      "last_update": "2007-10-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00298987",
      "title": "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2010-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00316953",
      "title": "Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2013-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00320190",
      "title": "Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib",
      "status": "TERMINATED",
      "last_update": "2013-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324077",
      "title": "Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "WITHDRAWN",
      "last_update": "2016-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324324",
      "title": "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-05-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00327262",
      "title": "Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase",
      "status": "UNKNOWN",
      "last_update": "2006-06-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00333840",
      "title": "Safety and Efficacy of Imatinib Versus Interferon-\u03b1 Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-10-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00337454",
      "title": "Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00345826",
      "title": "Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00349518",
      "title": "Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL",
      "status": "WITHDRAWN",
      "last_update": "2016-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00362466",
      "title": "A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy",
      "status": "TERMINATED",
      "last_update": "2009-11-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00363649",
      "title": "Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI",
      "status": "COMPLETED",
      "last_update": "2018-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00375219",
      "title": "Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation",
      "status": "COMPLETED",
      "last_update": "2021-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00376922",
      "title": "Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases",
      "status": "COMPLETED",
      "last_update": "2017-05-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00378781",
      "title": "Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection",
      "status": "WITHDRAWN",
      "last_update": "2012-02-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00384228",
      "title": "A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00390793",
      "title": "Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00390897",
      "title": "Glivec\u00ae (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec\u00ae-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2008-11-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00415857",
      "title": "Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)",
      "status": "TERMINATED",
      "last_update": "2018-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00416884",
      "title": "Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML",
      "status": "TERMINATED",
      "last_update": "2017-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00420043",
      "title": "Effect of Food on Bioavailability of Modified Release Formulations of Imatinib",
      "status": "COMPLETED",
      "last_update": "2016-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00422825",
      "title": "Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib",
      "status": "COMPLETED",
      "last_update": "2016-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00424242",
      "title": "Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases",
      "status": "COMPLETED",
      "last_update": "2021-09-08",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00428077",
      "title": "Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2011-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00428909",
      "title": "Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2016-04-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00449761",
      "title": "Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase",
      "status": "TERMINATED",
      "last_update": "2021-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00451035",
      "title": "Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase",
      "status": "TERMINATED",
      "last_update": "2021-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00455221",
      "title": "Safety Assessment of a Multipeptide-gene Vaccine in CML",
      "status": "COMPLETED",
      "last_update": "2012-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00460629",
      "title": "Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00461929",
      "title": "Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib",
      "status": "TERMINATED",
      "last_update": "2009-02-13",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00466726",
      "title": "Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00471497",
      "title": "A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2020-11-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00478985",
      "title": "Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-07-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00481052",
      "title": "Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2022-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00481247",
      "title": "A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-02-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00482703",
      "title": "A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-12-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00493181",
      "title": "Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients",
      "status": "COMPLETED",
      "last_update": "2012-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00500006",
      "title": "A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)",
      "status": "TERMINATED",
      "last_update": "2015-01-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00509691",
      "title": "Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy",
      "status": "COMPLETED",
      "last_update": "2017-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00510926",
      "title": "Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2007-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00511303",
      "title": "Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2007-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00513474",
      "title": "Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2017-05-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00519090",
      "title": "Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",
      "status": "TERMINATED",
      "last_update": "2011-11-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00529763",
      "title": "Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects",
      "status": "COMPLETED",
      "last_update": "2023-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00538109",
      "title": "An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec\u00ae/Gleevec\u00ae_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2015-12-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00538850",
      "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain",
      "status": "COMPLETED",
      "last_update": "2014-03-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00569283",
      "title": "Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant",
      "status": "COMPLETED",
      "last_update": "2013-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00573378",
      "title": "Imatinib or Nilotinib With Pegylated Interferon-\u03b12b in Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2023-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00574873",
      "title": "Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML",
      "status": "COMPLETED",
      "last_update": "2019-01-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00580281",
      "title": "Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors",
      "status": "COMPLETED",
      "last_update": "2013-10-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00589563",
      "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer",
      "status": "COMPLETED",
      "last_update": "2014-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00594555",
      "title": "A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2008-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00627666",
      "title": "Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer",
      "status": "COMPLETED",
      "last_update": "2013-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00644878",
      "title": "Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib",
      "status": "TERMINATED",
      "last_update": "2021-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00660920",
      "title": "Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2018-05-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00661180",
      "title": "Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec",
      "status": "COMPLETED",
      "last_update": "2014-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00666211",
      "title": "Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain",
      "status": "COMPLETED",
      "last_update": "2012-09-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00686218",
      "title": "Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691015",
      "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2017-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00702403",
      "title": "Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML",
      "status": "COMPLETED",
      "last_update": "2017-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00716911",
      "title": "Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2015-06-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00719563",
      "title": "American Ginseng in Treating Patients With Fatigue Caused by Cancer",
      "status": "COMPLETED",
      "last_update": "2017-02-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00726830",
      "title": "Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer",
      "status": "TERMINATED",
      "last_update": "2020-09-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00732186",
      "title": "Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2016-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00750009",
      "title": "Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial",
      "status": "COMPLETED",
      "last_update": "2020-07-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00750659",
      "title": "Nilotinib Pre and Post Allogeneic Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2016-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00755040",
      "title": "Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder",
      "status": "COMPLETED",
      "last_update": "2017-03-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00759837",
      "title": "Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects",
      "status": "COMPLETED",
      "last_update": "2009-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00760877",
      "title": "Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)",
      "status": "COMPLETED",
      "last_update": "2016-11-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00763763",
      "title": "Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive",
      "status": "COMPLETED",
      "last_update": "2011-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00769327",
      "title": "Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00769613",
      "title": "Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections",
      "status": "UNKNOWN",
      "last_update": "2013-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00777036",
      "title": "A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib",
      "status": "COMPLETED",
      "last_update": "2025-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00782145",
      "title": "A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families",
      "status": "COMPLETED",
      "last_update": "2011-07-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00786812",
      "title": "Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2017-02-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00787761",
      "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer",
      "status": "COMPLETED",
      "last_update": "2012-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00802841",
      "title": "Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib",
      "status": "COMPLETED",
      "last_update": "2015-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00806767",
      "title": "Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer",
      "status": "COMPLETED",
      "last_update": "2011-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00809211",
      "title": "Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00811070",
      "title": "Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias",
      "status": "COMPLETED",
      "last_update": "2016-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00816283",
      "title": "Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2012-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00823524",
      "title": "Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00845221",
      "title": "Glivec in Pediatric Chronic Myeloid Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2016-10-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00852566",
      "title": "Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00852709",
      "title": "Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias",
      "status": "TERMINATED",
      "last_update": "2018-02-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00858806",
      "title": "Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy",
      "status": "COMPLETED",
      "last_update": "2014-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00860535",
      "title": "Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)",
      "status": "TERMINATED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00866736",
      "title": "A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00895297",
      "title": "Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2011-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00935090",
      "title": "3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": null,
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00946283",
      "title": "Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome",
      "status": "TERMINATED",
      "last_update": "2017-02-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00951626",
      "title": "A Standardized Nursing Intervention Protocol for HCT Patients",
      "status": "COMPLETED",
      "last_update": "2015-06-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00952185",
      "title": "Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers",
      "status": "TERMINATED",
      "last_update": "2015-06-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00955916",
      "title": "CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)",
      "status": "COMPLETED",
      "last_update": "2014-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00978731",
      "title": "Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study",
      "status": "COMPLETED",
      "last_update": "2011-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00980018",
      "title": "An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment",
      "status": "COMPLETED",
      "last_update": "2021-07-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00982488",
      "title": "Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01030718",
      "title": "Rollover Study of BMS-354825 in Patients With CML and Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2010-12-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01043874",
      "title": "Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response",
      "status": "COMPLETED",
      "last_update": "2016-04-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01061177",
      "title": "Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2017-02-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01066468",
      "title": "Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec\u00ae Indicated Hematological Disorders.",
      "status": "TERMINATED",
      "last_update": "2012-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01077544",
      "title": "A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2020-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101412",
      "title": "Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2013-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01114087",
      "title": "Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility",
      "status": "COMPLETED",
      "last_update": "2011-03-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01116232",
      "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2019-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01118013",
      "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01126892",
      "title": "A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2017-02-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01131325",
      "title": "Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations",
      "status": "TERMINATED",
      "last_update": "2021-05-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01158118",
      "title": "Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors",
      "status": "COMPLETED",
      "last_update": "2017-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01164163",
      "title": "INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",
      "status": "COMPLETED",
      "last_update": "2014-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01169753",
      "title": "Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients",
      "status": "TERMINATED",
      "last_update": "2015-12-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01206088",
      "title": "Tasigna in Glivec-resistant or Intolerant Patients in CML",
      "status": "COMPLETED",
      "last_update": "2017-02-28",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207440",
      "title": "Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2021-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216085",
      "title": "An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints",
      "status": "COMPLETED",
      "last_update": "2021-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01218477",
      "title": "Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2016-06-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01220648",
      "title": "Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2015-05-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01221376",
      "title": "Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)",
      "status": "UNKNOWN",
      "last_update": "2013-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01223898",
      "title": "To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib",
      "status": "COMPLETED",
      "last_update": "2020-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01227135",
      "title": "Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2011-11-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01227356",
      "title": "A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-10-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01227577",
      "title": "CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib",
      "status": "COMPLETED",
      "last_update": "2016-02-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01243489",
      "title": "Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation",
      "status": "COMPLETED",
      "last_update": "2019-12-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01254188",
      "title": "Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients",
      "status": "COMPLETED",
      "last_update": "2016-03-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01270984",
      "title": "Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects",
      "status": "COMPLETED",
      "last_update": "2012-10-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01274351",
      "title": "Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2020-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01275196",
      "title": "Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients",
      "status": "COMPLETED",
      "last_update": "2016-04-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01279473",
      "title": "Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01294618",
      "title": "Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01316250",
      "title": "Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-10-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01316744",
      "title": "Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain",
      "status": "UNKNOWN",
      "last_update": "2011-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01342679",
      "title": "A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib",
      "status": "COMPLETED",
      "last_update": "2015-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01343173",
      "title": "Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib",
      "status": "COMPLETED",
      "last_update": "2026-07-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01357655",
      "title": "Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)",
      "status": "TERMINATED",
      "last_update": "2017-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01368523",
      "title": "Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial",
      "status": "COMPLETED",
      "last_update": "2016-11-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01374139",
      "title": "Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects",
      "status": "COMPLETED",
      "last_update": "2011-11-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01392170",
      "title": "Pegasys in Patients With Chronic Myeloid Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2015-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01397734",
      "title": "Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2018-09-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01400074",
      "title": "Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib",
      "status": "UNKNOWN",
      "last_update": "2014-01-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01424982",
      "title": "Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01426334",
      "title": "Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate",
      "status": "TERMINATED",
      "last_update": "2014-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01456676",
      "title": "Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy",
      "status": "COMPLETED",
      "last_update": "2020-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01460498",
      "title": "Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2020-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01460693",
      "title": "Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2018-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01490775",
      "title": "Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy",
      "status": "TERMINATED",
      "last_update": "2018-08-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01490983",
      "title": "Telemonitoring Study - for Chronic Myeloid Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2018-08-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01498445",
      "title": "An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)",
      "status": "TERMINATED",
      "last_update": "2020-10-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01503502",
      "title": "A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-04-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01511289",
      "title": "Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients",
      "status": "COMPLETED",
      "last_update": "2016-02-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01535391",
      "title": "Nilotinib in PH+, BCR-, ABL+ CML Patients",
      "status": "COMPLETED",
      "last_update": "2018-08-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01570868",
      "title": "Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)",
      "status": "TERMINATED",
      "last_update": "2025-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01593254",
      "title": "Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib",
      "status": "COMPLETED",
      "last_update": "2023-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01602952",
      "title": "Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI",
      "status": "COMPLETED",
      "last_update": "2018-08-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01605981",
      "title": "Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.",
      "status": "WITHDRAWN",
      "last_update": "2017-04-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01606579",
      "title": "Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01627132",
      "title": "Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial",
      "status": "UNKNOWN",
      "last_update": "2012-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01643603",
      "title": "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2020-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01650805",
      "title": "Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)",
      "status": "TERMINATED",
      "last_update": "2014-11-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01657604",
      "title": "TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study",
      "status": "COMPLETED",
      "last_update": "2023-05-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01660906",
      "title": "Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib",
      "status": "COMPLETED",
      "last_update": "2016-11-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01667133",
      "title": "A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2022-06-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01670084",
      "title": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2015-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01690065",
      "title": "Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML",
      "status": "UNKNOWN",
      "last_update": "2016-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01698905",
      "title": "Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)",
      "status": "COMPLETED",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01702064",
      "title": "Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients",
      "status": "COMPLETED",
      "last_update": "2021-01-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01725204",
      "title": "Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01735955",
      "title": "Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study",
      "status": "COMPLETED",
      "last_update": "2024-02-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01742299",
      "title": "Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01743989",
      "title": "A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.",
      "status": "COMPLETED",
      "last_update": "2021-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01744665",
      "title": "A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation",
      "status": "COMPLETED",
      "last_update": "2020-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01751425",
      "title": "Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01751919",
      "title": "A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)",
      "status": "COMPLETED",
      "last_update": "2014-10-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01755325",
      "title": "Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+",
      "status": "SUSPENDED",
      "last_update": "2018-04-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01774630",
      "title": "Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)",
      "status": "COMPLETED",
      "last_update": "2026-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01784068",
      "title": "Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients",
      "status": "COMPLETED",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01802450",
      "title": "Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "UNKNOWN",
      "last_update": "2015-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01804985",
      "title": "De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2025-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01819389",
      "title": "Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance",
      "status": "COMPLETED",
      "last_update": "2014-01-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01844765",
      "title": "Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.",
      "status": "COMPLETED",
      "last_update": "2021-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01850004",
      "title": "Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response",
      "status": "COMPLETED",
      "last_update": "2022-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01856283",
      "title": "Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells",
      "status": "COMPLETED",
      "last_update": "2021-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01866553",
      "title": "Nilotinib Plus Pegylated Interferon-\u03b12b in CML",
      "status": "TERMINATED",
      "last_update": "2018-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01872442",
      "title": "Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2020-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01887561",
      "title": "Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial",
      "status": "UNKNOWN",
      "last_update": "2013-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01903733",
      "title": "Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008",
      "status": "COMPLETED",
      "last_update": "2022-07-19",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914484",
      "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01916785",
      "title": "OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)",
      "status": "COMPLETED",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01933906",
      "title": "Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response",
      "status": "COMPLETED",
      "last_update": "2019-01-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02001818",
      "title": "Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2024-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02011945",
      "title": "A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02047149",
      "title": "Evaluating the Safety of Zileuton (Zyflo\u00ae) in Combination With Dasatinib (Sprycel\u00ae) in Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2016-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02058277",
      "title": "A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers",
      "status": "COMPLETED",
      "last_update": "2014-06-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081378",
      "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02086487",
      "title": "Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy",
      "status": "TERMINATED",
      "last_update": "2017-03-07",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02108951",
      "title": "Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.",
      "status": "TERMINATED",
      "last_update": "2017-10-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115386",
      "title": "Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib",
      "status": "TERMINATED",
      "last_update": "2019-12-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115672",
      "title": "Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2016-08-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02130557",
      "title": "A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02174445",
      "title": "An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response \u2265 4 Log (MR4) at Two Years",
      "status": "TERMINATED",
      "last_update": "2019-12-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02201459",
      "title": "Nilotinib \u00b1 Peg-IFN for First Line Chronic Phase CML Patients",
      "status": "COMPLETED",
      "last_update": "2025-10-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02204644",
      "title": "The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML",
      "status": "COMPLETED",
      "last_update": "2018-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02204722",
      "title": "A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients",
      "status": "TERMINATED",
      "last_update": "2018-06-15",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02225574",
      "title": "An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",
      "status": "TERMINATED",
      "last_update": "2020-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02228382",
      "title": "Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors",
      "status": "TERMINATED",
      "last_update": "2021-12-30",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02253277",
      "title": "Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients",
      "status": "COMPLETED",
      "last_update": "2019-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02268370",
      "title": "Treatment-free Remission Accomplished With Dasatinib in Patients With CML",
      "status": "UNKNOWN",
      "last_update": "2019-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02269267",
      "title": "The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)",
      "status": "COMPLETED",
      "last_update": "2023-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02272777",
      "title": "A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02311998",
      "title": "Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML",
      "status": "COMPLETED",
      "last_update": "2023-07-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02326311",
      "title": "Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients \u226560 Years in Deep Molecular Response",
      "status": "COMPLETED",
      "last_update": "2024-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02352558",
      "title": "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02353728",
      "title": "Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy",
      "status": "COMPLETED",
      "last_update": "2022-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02381379",
      "title": "Malaysia Stop Tyrosine Kinase Inhibitor Trial",
      "status": "UNKNOWN",
      "last_update": "2020-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02389920",
      "title": "Multicenter, Phase\u2163, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib",
      "status": "UNKNOWN",
      "last_update": "2015-03-17",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02398825",
      "title": "Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib",
      "status": "TERMINATED",
      "last_update": "2025-01-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02467270",
      "title": "Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses",
      "status": "COMPLETED",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02480608",
      "title": "Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)",
      "status": "COMPLETED",
      "last_update": "2015-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02546674",
      "title": "Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.",
      "status": "COMPLETED",
      "last_update": "2022-07-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02602314",
      "title": "Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-01-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02627573",
      "title": "Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT",
      "status": "TERMINATED",
      "last_update": "2019-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02627677",
      "title": "A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02629692",
      "title": "Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to \u22653 Prior CML Therapies",
      "status": "TERMINATED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02638467",
      "title": "Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy",
      "status": "COMPLETED",
      "last_update": "2020-11-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02687425",
      "title": "Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2016-02-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02689440",
      "title": "Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02709083",
      "title": "Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2018-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02782403",
      "title": "Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2020-11-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02810990",
      "title": "Bosutinib in Elderly Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02852486",
      "title": "Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02885766",
      "title": "Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene",
      "status": "UNKNOWN",
      "last_update": "2020-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890784",
      "title": "Dasatinib Holiday for Improved Tolerability",
      "status": "COMPLETED",
      "last_update": "2023-05-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02896842",
      "title": "A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML",
      "status": "COMPLETED",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02906696",
      "title": "Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure",
      "status": "TERMINATED",
      "last_update": "2020-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02917720",
      "title": "2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02923986",
      "title": "Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS",
      "status": "WITHDRAWN",
      "last_update": "2020-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02973711",
      "title": "A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML",
      "status": "WITHDRAWN",
      "last_update": "2021-02-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03062436",
      "title": "To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission",
      "status": "UNKNOWN",
      "last_update": "2019-07-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03079505",
      "title": "Dasatinib Versus Nilotinib for Treatment Na\u00efve Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2019-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03106779",
      "title": "Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03128411",
      "title": "Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03147612",
      "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03193281",
      "title": "KISS Study: Kinase Inhibition With Sprycel Start up",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03205267",
      "title": "Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients",
      "status": "UNKNOWN",
      "last_update": "2017-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03214718",
      "title": "Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-07-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03216070",
      "title": "Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-07-13",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228303",
      "title": "Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-10-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03239886",
      "title": "Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log",
      "status": "UNKNOWN",
      "last_update": "2018-03-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03332511",
      "title": "Efficacy and Safety of Nilotinib in CML-CP",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03414450",
      "title": "Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2018-10-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03515018",
      "title": "Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients",
      "status": "UNKNOWN",
      "last_update": "2018-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03516279",
      "title": "Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03573596",
      "title": "Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment",
      "status": "UNKNOWN",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03576547",
      "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03578367",
      "title": "Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610971",
      "title": "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03625388",
      "title": "Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654768",
      "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03722420",
      "title": "Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03807479",
      "title": "Study in Patients With Chronic Leukemia",
      "status": "TERMINATED",
      "last_update": "2023-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03831776",
      "title": "Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03874858",
      "title": "A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03882281",
      "title": "Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-01-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03883087",
      "title": "A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation",
      "status": "UNKNOWN",
      "last_update": "2023-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03883100",
      "title": "A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation",
      "status": "UNKNOWN",
      "last_update": "2023-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03895671",
      "title": "PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS",
      "status": "COMPLETED",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03906292",
      "title": "Frontline Asciminib Combination in Chronic Phase CML",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03942094",
      "title": "Nilotinib for First-line Newly Diagnosed CML-CP Patients",
      "status": "UNKNOWN",
      "last_update": "2022-03-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04006847",
      "title": "Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-07-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04043676",
      "title": "Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2019-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04070443",
      "title": "Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126681",
      "title": "A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126707",
      "title": "The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans",
      "status": "COMPLETED",
      "last_update": "2021-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04147533",
      "title": "Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04155411",
      "title": "Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP",
      "status": "UNKNOWN",
      "last_update": "2022-07-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04160546",
      "title": "Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04188405",
      "title": "Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04216563",
      "title": "ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor",
      "status": "TERMINATED",
      "last_update": "2026-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04233346",
      "title": "The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04258943",
      "title": "Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578847",
      "title": "A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)",
      "status": "UNKNOWN",
      "last_update": "2020-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04605211",
      "title": "A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors",
      "status": "COMPLETED",
      "last_update": "2023-02-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626024",
      "title": "Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04637009",
      "title": "A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms",
      "status": "TERMINATED",
      "last_update": "2024-08-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04666259",
      "title": "Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation",
      "status": "COMPLETED",
      "last_update": "2025-10-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04677439",
      "title": "Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure",
      "status": "UNKNOWN",
      "last_update": "2022-03-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04709731",
      "title": "Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04793399",
      "title": "Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients",
      "status": "TERMINATED",
      "last_update": "2024-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04795427",
      "title": "Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors",
      "status": "COMPLETED",
      "last_update": "2025-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835584",
      "title": "KRT-232 and TKI Study in Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04883125",
      "title": "Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment",
      "status": "COMPLETED",
      "last_update": "2021-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04925141",
      "title": "A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2021-06-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04933526",
      "title": "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients",
      "status": "UNKNOWN",
      "last_update": "2022-07-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04948333",
      "title": "Asciminib Treatment Optimization in \u2265 3rd Line CML-CP",
      "status": "COMPLETED",
      "last_update": "2026-03-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971226",
      "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05007873",
      "title": "ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05143840",
      "title": "Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05311943",
      "title": "Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.",
      "status": "UNKNOWN",
      "last_update": "2022-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05353205",
      "title": "A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.",
      "status": "UNKNOWN",
      "last_update": "2022-04-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05367765",
      "title": "A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-05-10",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05376852",
      "title": "Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML",
      "status": "UNKNOWN",
      "last_update": "2022-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05384587",
      "title": "Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05413915",
      "title": "Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML",
      "status": "TERMINATED",
      "last_update": "2026-05-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05433532",
      "title": "Study of Azacitidine\uff0cVenetoclax\uff0cand Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients",
      "status": "COMPLETED",
      "last_update": "2024-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05456191",
      "title": "A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (\u226518 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05638763",
      "title": "Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05640804",
      "title": "A Bioequivalence Study of Dasatinib Tablet",
      "status": "COMPLETED",
      "last_update": "2022-12-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427811",
      "title": "Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation",
      "status": "COMPLETED",
      "last_update": "2026-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06672263",
      "title": "A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07022743",
      "title": "Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07158294",
      "title": "Identification of BCR::ABL1 Mutations by Digital PCR in CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493408",
      "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07538401",
      "title": "ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07604233",
      "title": "Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07789574",
      "title": "Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07804901",
      "title": "Asciminib Frontline Risk Adapted",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 4,
     "n_observational": 2,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT00104975",
       "title": "Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer",
       "status": "COMPLETED",
       "last_update": "2016-12-15",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00460629",
       "title": "Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation",
       "status": "COMPLETED",
       "last_update": "2013-06-20",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00769613",
       "title": "Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections",
       "status": "UNKNOWN",
       "last_update": "2013-12-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00806767",
       "title": "Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer",
       "status": "COMPLETED",
       "last_update": "2011-05-17",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "BCR-ABL",
     "BCR::ABL1",
     "imatinib",
     "Gleevec",
     "dasatinib",
     "Sprycel",
     "nilotinib",
     "Tasigna",
     "bosutinib",
     "Bosulif",
     "ponatinib",
     "Iclusig",
     "asciminib",
     "Scemblix",
     "olverembatinib",
     "vodobatinib"
    ]
   },
   "interferon": {
    "n": 59,
    "n_observational": 2,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT07269470",
      "title": "Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002504",
      "title": "Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2011-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002574",
      "title": "Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002598",
      "title": "Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002771",
      "title": "Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-08-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002868",
      "title": "Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-06-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002869",
      "title": "Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003239",
      "title": "Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2012-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003408",
      "title": "Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer",
      "status": "COMPLETED",
      "last_update": "2013-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003451",
      "title": "Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003561",
      "title": "Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2011-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003727",
      "title": "Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004905",
      "title": "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004933",
      "title": "Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa",
      "status": "TERMINATED",
      "last_update": "2016-07-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005948",
      "title": "Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005984",
      "title": "Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005986",
      "title": "Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006053",
      "title": "STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa",
      "status": "COMPLETED",
      "last_update": "2013-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006091",
      "title": "Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment",
      "status": "WITHDRAWN",
      "last_update": "2018-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006343",
      "title": "STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00011934",
      "title": "Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00015847",
      "title": "Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025402",
      "title": "Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00037882",
      "title": "PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron",
      "status": "TERMINATED",
      "last_update": "2018-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00038649",
      "title": "Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C",
      "status": "TERMINATED",
      "last_update": "2018-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00045422",
      "title": "Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00050531",
      "title": "High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2016-05-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00055874",
      "title": "Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-05-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110058",
      "title": "Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171223",
      "title": "An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha",
      "status": "COMPLETED",
      "last_update": "2021-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00303290",
      "title": "PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML",
      "status": "COMPLETED",
      "last_update": "2015-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00333840",
      "title": "Safety and Efficacy of Imatinib Versus Interferon-\u03b1 Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-10-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00363649",
      "title": "Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI",
      "status": "COMPLETED",
      "last_update": "2018-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00390897",
      "title": "Glivec\u00ae (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec\u00ae-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2008-11-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00415857",
      "title": "Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)",
      "status": "TERMINATED",
      "last_update": "2018-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00452023",
      "title": "Pegasys\u00ae in Patients With Myeloproliferative Diseases",
      "status": "COMPLETED",
      "last_update": "2024-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00511121",
      "title": "Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)",
      "status": "TERMINATED",
      "last_update": "2007-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00548847",
      "title": "Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation",
      "status": "COMPLETED",
      "last_update": "2016-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00573378",
      "title": "Imatinib or Nilotinib With Pegylated Interferon-\u03b12b in Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2023-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00763763",
      "title": "Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive",
      "status": "COMPLETED",
      "last_update": "2011-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01220648",
      "title": "Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2015-05-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01227356",
      "title": "A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-10-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01294618",
      "title": "Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01392170",
      "title": "Pegasys in Patients With Chronic Myeloid Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2015-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01657604",
      "title": "TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study",
      "status": "COMPLETED",
      "last_update": "2023-05-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01725204",
      "title": "Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01866553",
      "title": "Nilotinib Plus Pegylated Interferon-\u03b12b in CML",
      "status": "TERMINATED",
      "last_update": "2018-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01872442",
      "title": "Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2020-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01933906",
      "title": "Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response",
      "status": "COMPLETED",
      "last_update": "2019-01-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02001818",
      "title": "Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2024-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02201459",
      "title": "Nilotinib \u00b1 Peg-IFN for First Line Chronic Phase CML Patients",
      "status": "COMPLETED",
      "last_update": "2025-10-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02381379",
      "title": "Malaysia Stop Tyrosine Kinase Inhibitor Trial",
      "status": "UNKNOWN",
      "last_update": "2020-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02736721",
      "title": "Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2016-09-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02829775",
      "title": "A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys\u00ae) or Recombinant Interferon Alfa-2a (Roferon-A\u00ae) in Prior Clinical Studies",
      "status": "COMPLETED",
      "last_update": "2017-01-09",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03117816",
      "title": "ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission",
      "status": "COMPLETED",
      "last_update": "2023-03-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547154",
      "title": "Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^\u00ae A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)",
      "status": "TERMINATED",
      "last_update": "2019-08-12",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03831776",
      "title": "Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07105319",
      "title": "Ropeginterferon for Treatment Free Remission",
      "status": "COMPLETED",
      "last_update": "2025-08-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07468916",
      "title": "Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "interferon alfa",
     "peginterferon",
     "ropeginterferon"
    ]
   },
   "BCL-2": {
    "n": 55,
    "n_observational": 4,
    "n_active": 25,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT02115295",
      "title": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03850574",
      "title": "Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2025-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04140487",
      "title": "Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04256317",
      "title": "A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)",
      "status": "RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04581512",
      "title": "Study to Evaluate the Safety and Tolerability of EP0042",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04588922",
      "title": "Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04708054",
      "title": "Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05184842",
      "title": "Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05584761",
      "title": "Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML",
      "status": "RECRUITING",
      "last_update": "2022-10-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05641259",
      "title": "A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05807932",
      "title": "Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML",
      "status": "RECRUITING",
      "last_update": "2024-05-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06757855",
      "title": "Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML",
      "status": "RECRUITING",
      "last_update": "2025-05-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06778187",
      "title": "Oral-ATO for TP53-mutated Myeloid Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049192",
      "title": "Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00933985",
      "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia",
      "status": "TERMINATED",
      "last_update": "2014-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02265731",
      "title": "Study Evaluating Venetoclax in Subjects With Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-08-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02397720",
      "title": "Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02689440",
      "title": "Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03404193",
      "title": "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome",
      "status": "TERMINATED",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03455517",
      "title": "Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547115",
      "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML",
      "status": "TERMINATED",
      "last_update": "2026-03-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03576547",
      "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03613532",
      "title": "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03755154",
      "title": "Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2024-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03844048",
      "title": "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03862157",
      "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03922100",
      "title": "Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML",
      "status": "TERMINATED",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04146038",
      "title": "Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease",
      "status": "COMPLETED",
      "last_update": "2023-05-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04160052",
      "title": "Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome",
      "status": "TERMINATED",
      "last_update": "2026-02-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04188405",
      "title": "Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04372433",
      "title": "IO-202 as Monotherapy and IO-202 Plus Azacitidine \u00b1 Venetoclax in Patients in AML and CMML",
      "status": "COMPLETED",
      "last_update": "2025-02-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04477291",
      "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS",
      "status": "TERMINATED",
      "last_update": "2025-03-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04487106",
      "title": "Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2025-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04512105",
      "title": "Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04550442",
      "title": "Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04553692",
      "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers",
      "status": "TERMINATED",
      "last_update": "2025-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04603001",
      "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04609826",
      "title": "A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",
      "status": "COMPLETED",
      "last_update": "2025-10-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04655755",
      "title": "Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04752163",
      "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04937166",
      "title": "A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-11-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05107856",
      "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05201066",
      "title": "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05209152",
      "title": "AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05428969",
      "title": "A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05433532",
      "title": "Study of Azacitidine\uff0cVenetoclax\uff0cand Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients",
      "status": "COMPLETED",
      "last_update": "2024-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05600894",
      "title": "Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05701215",
      "title": "Venetoclax After TKI to Target Persisting Stem Cells in CML",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05768711",
      "title": "Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06085638",
      "title": "Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2024-03-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563804",
      "title": "A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML",
      "status": "TERMINATED",
      "last_update": "2026-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07082452",
      "title": "A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Na\u00efve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-07-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07604233",
      "title": "Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "BCL-2",
     "venetoclax"
    ]
   },
   "PD-1": {
    "n": 7,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01822509",
      "title": "Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2021-06-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02011945",
      "title": "A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02397720",
      "title": "Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03066648",
      "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS",
      "status": "COMPLETED",
      "last_update": "2025-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03358719",
      "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03516279",
      "title": "Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PD-1",
     "nivolumab",
     "pembrolizumab"
    ]
   }
  },
  "by_drug": {
   "APG-2575": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04964518",
      "title": "A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)",
      "status": "UNKNOWN",
      "last_update": "2023-10-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ASCIMINIB": {
    "n": 30,
    "n_observational": 14,
    "n_active": 20,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03595917",
      "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",
      "status": "RECRUITING",
      "last_update": "2025-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04838041",
      "title": "Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04877522",
      "title": "Asciminib Roll-over Study",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04925479",
      "title": "Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06236724",
      "title": "Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06368414",
      "title": "A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06409936",
      "title": "PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML",
      "status": "RECRUITING",
      "last_update": "2025-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06514534",
      "title": "Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.",
      "status": "RECRUITING",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06629584",
      "title": "Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07354074",
      "title": "Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081378",
      "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03106779",
      "title": "Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03578367",
      "title": "Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03874858",
      "title": "A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03906292",
      "title": "Frontline Asciminib Combination in Chronic Phase CML",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04216563",
      "title": "ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor",
      "status": "TERMINATED",
      "last_update": "2026-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04666259",
      "title": "Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation",
      "status": "COMPLETED",
      "last_update": "2025-10-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04795427",
      "title": "Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors",
      "status": "COMPLETED",
      "last_update": "2025-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04948333",
      "title": "Asciminib Treatment Optimization in \u2265 3rd Line CML-CP",
      "status": "COMPLETED",
      "last_update": "2026-03-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971226",
      "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05143840",
      "title": "Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05384587",
      "title": "Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05413915",
      "title": "Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML",
      "status": "TERMINATED",
      "last_update": "2026-05-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05456191",
      "title": "A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (\u226518 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427811",
      "title": "Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation",
      "status": "COMPLETED",
      "last_update": "2026-06-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493408",
      "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07538401",
      "title": "ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07604233",
      "title": "Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07789574",
      "title": "Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07804901",
      "title": "Asciminib Frontline Risk Adapted",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AT-9283": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00522990",
      "title": "Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias",
      "status": "TERMINATED",
      "last_update": "2024-08-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BAFETINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00352677",
      "title": "Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2009-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BOSUTINIB": {
    "n": 30,
    "n_observational": 14,
    "n_active": 7,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04877522",
      "title": "Asciminib Roll-over Study",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06423911",
      "title": "Study of Olverembatinib (HQP1351) in Patients With CP-CML",
      "status": "RECRUITING",
      "last_update": "2025-06-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00261846",
      "title": "Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias",
      "status": "COMPLETED",
      "last_update": "2017-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00574873",
      "title": "Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML",
      "status": "COMPLETED",
      "last_update": "2019-01-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00759837",
      "title": "Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects",
      "status": "COMPLETED",
      "last_update": "2009-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00811070",
      "title": "Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias",
      "status": "COMPLETED",
      "last_update": "2016-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01374139",
      "title": "Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects",
      "status": "COMPLETED",
      "last_update": "2011-11-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01903733",
      "title": "Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008",
      "status": "COMPLETED",
      "last_update": "2022-07-19",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02058277",
      "title": "A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers",
      "status": "COMPLETED",
      "last_update": "2014-06-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02130557",
      "title": "A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02228382",
      "title": "Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors",
      "status": "TERMINATED",
      "last_update": "2021-12-30",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02269267",
      "title": "The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)",
      "status": "COMPLETED",
      "last_update": "2023-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02311998",
      "title": "Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML",
      "status": "COMPLETED",
      "last_update": "2023-07-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02638467",
      "title": "Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy",
      "status": "COMPLETED",
      "last_update": "2020-11-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02782403",
      "title": "Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2020-11-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02810990",
      "title": "Bosutinib in Elderly Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02906696",
      "title": "Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure",
      "status": "TERMINATED",
      "last_update": "2020-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03106779",
      "title": "Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03128411",
      "title": "Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03205267",
      "title": "Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients",
      "status": "UNKNOWN",
      "last_update": "2017-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610971",
      "title": "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654768",
      "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03831776",
      "title": "Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04006847",
      "title": "Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-07-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04258943",
      "title": "Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578847",
      "title": "A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)",
      "status": "UNKNOWN",
      "last_update": "2020-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626024",
      "title": "Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04709731",
      "title": "Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04793399",
      "title": "Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients",
      "status": "TERMINATED",
      "last_update": "2024-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971226",
      "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DASATINIB": {
    "n": 111,
    "n_observational": 36,
    "n_active": 19,
    "n_withdrawn": 5,
    "trials": [
     {
      "nct": "NCT01746836",
      "title": "Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03595917",
      "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",
      "status": "RECRUITING",
      "last_update": "2025-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04838041",
      "title": "Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04877522",
      "title": "Asciminib Roll-over Study",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07269470",
      "title": "Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00036738",
      "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "COMPLETED",
      "last_update": "2020-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00064233",
      "title": "BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070499",
      "title": "Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101595",
      "title": "Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101647",
      "title": "Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101660",
      "title": "Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib",
      "status": "COMPLETED",
      "last_update": "2012-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101816",
      "title": "Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2010-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00103701",
      "title": "BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00103844",
      "title": "Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00112775",
      "title": "BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate",
      "status": "UNKNOWN",
      "last_update": "2011-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00123474",
      "title": "Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML",
      "status": "COMPLETED",
      "last_update": "2016-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00123487",
      "title": "Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML",
      "status": "COMPLETED",
      "last_update": "2014-11-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00254423",
      "title": "Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00255346",
      "title": "Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)",
      "status": "COMPLETED",
      "last_update": "2025-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00298987",
      "title": "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2010-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00316953",
      "title": "Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2013-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00320190",
      "title": "Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib",
      "status": "TERMINATED",
      "last_update": "2013-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324077",
      "title": "Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "WITHDRAWN",
      "last_update": "2016-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00337454",
      "title": "Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00345826",
      "title": "Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00349518",
      "title": "Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL",
      "status": "WITHDRAWN",
      "last_update": "2016-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00362466",
      "title": "A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy",
      "status": "TERMINATED",
      "last_update": "2009-11-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00390793",
      "title": "Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00481247",
      "title": "A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-02-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00482703",
      "title": "A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-12-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00500006",
      "title": "A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)",
      "status": "TERMINATED",
      "last_update": "2015-01-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00529763",
      "title": "Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects",
      "status": "COMPLETED",
      "last_update": "2023-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00732186",
      "title": "Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2016-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00777036",
      "title": "A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib",
      "status": "COMPLETED",
      "last_update": "2025-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00816283",
      "title": "Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2012-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00852566",
      "title": "Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00860535",
      "title": "Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)",
      "status": "TERMINATED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00866736",
      "title": "A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00895297",
      "title": "Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2011-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00978731",
      "title": "Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study",
      "status": "COMPLETED",
      "last_update": "2011-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00982488",
      "title": "Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01030718",
      "title": "Rollover Study of BMS-354825 in Patients With CML and Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2010-12-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01077544",
      "title": "A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2020-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01169753",
      "title": "Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients",
      "status": "TERMINATED",
      "last_update": "2015-12-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207440",
      "title": "Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2021-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01218477",
      "title": "Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2016-06-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01342679",
      "title": "A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib",
      "status": "COMPLETED",
      "last_update": "2015-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01357655",
      "title": "Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)",
      "status": "TERMINATED",
      "last_update": "2017-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01397734",
      "title": "Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2018-09-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01426334",
      "title": "Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate",
      "status": "TERMINATED",
      "last_update": "2014-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01460693",
      "title": "Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2018-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01498445",
      "title": "An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)",
      "status": "TERMINATED",
      "last_update": "2020-10-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01593254",
      "title": "Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib",
      "status": "COMPLETED",
      "last_update": "2023-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01602952",
      "title": "Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI",
      "status": "COMPLETED",
      "last_update": "2018-08-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01606579",
      "title": "Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01627132",
      "title": "Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial",
      "status": "UNKNOWN",
      "last_update": "2012-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01643603",
      "title": "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2020-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01660906",
      "title": "Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib",
      "status": "COMPLETED",
      "last_update": "2016-11-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01667133",
      "title": "A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2022-06-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01725204",
      "title": "Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01751425",
      "title": "Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01802450",
      "title": "Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "UNKNOWN",
      "last_update": "2015-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01804985",
      "title": "De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2025-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01844765",
      "title": "Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.",
      "status": "COMPLETED",
      "last_update": "2021-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01850004",
      "title": "Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response",
      "status": "COMPLETED",
      "last_update": "2022-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01872442",
      "title": "Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2020-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01887561",
      "title": "Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial",
      "status": "UNKNOWN",
      "last_update": "2013-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01916785",
      "title": "OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)",
      "status": "COMPLETED",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02011945",
      "title": "A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02047149",
      "title": "Evaluating the Safety of Zileuton (Zyflo\u00ae) in Combination With Dasatinib (Sprycel\u00ae) in Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2016-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081378",
      "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02108951",
      "title": "Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.",
      "status": "TERMINATED",
      "last_update": "2017-10-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02268370",
      "title": "Treatment-free Remission Accomplished With Dasatinib in Patients With CML",
      "status": "UNKNOWN",
      "last_update": "2019-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02269267",
      "title": "The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)",
      "status": "COMPLETED",
      "last_update": "2023-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02326311",
      "title": "Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients \u226560 Years in Deep Molecular Response",
      "status": "COMPLETED",
      "last_update": "2024-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02389920",
      "title": "Multicenter, Phase\u2163, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib",
      "status": "UNKNOWN",
      "last_update": "2015-03-17",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02689440",
      "title": "Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02709083",
      "title": "Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2018-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890784",
      "title": "Dasatinib Holiday for Improved Tolerability",
      "status": "COMPLETED",
      "last_update": "2023-05-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02923986",
      "title": "Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS",
      "status": "WITHDRAWN",
      "last_update": "2020-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03079505",
      "title": "Dasatinib Versus Nilotinib for Treatment Na\u00efve Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2019-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03193281",
      "title": "KISS Study: Kinase Inhibition With Sprycel Start up",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03205267",
      "title": "Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients",
      "status": "UNKNOWN",
      "last_update": "2017-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03216070",
      "title": "Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-07-13",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03414450",
      "title": "Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2018-10-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03516279",
      "title": "Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03573596",
      "title": "Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment",
      "status": "UNKNOWN",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610971",
      "title": "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03625388",
      "title": "Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654768",
      "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03906292",
      "title": "Frontline Asciminib Combination in Chronic Phase CML",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04006847",
      "title": "Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-07-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126681",
      "title": "A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04147533",
      "title": "Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04155411",
      "title": "Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP",
      "status": "UNKNOWN",
      "last_update": "2022-07-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04216563",
      "title": "ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor",
      "status": "TERMINATED",
      "last_update": "2026-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578847",
      "title": "A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)",
      "status": "UNKNOWN",
      "last_update": "2020-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626024",
      "title": "Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835584",
      "title": "KRT-232 and TKI Study in Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04925141",
      "title": "A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2021-06-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04933526",
      "title": "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients",
      "status": "UNKNOWN",
      "last_update": "2022-07-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971226",
      "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05007873",
      "title": "ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05143840",
      "title": "Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05638763",
      "title": "Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05640804",
      "title": "A Bioequivalence Study of Dasatinib Tablet",
      "status": "COMPLETED",
      "last_update": "2022-12-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493408",
      "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07538401",
      "title": "ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07804901",
      "title": "Asciminib Frontline Risk Adapted",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EPRENETAPOPT": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03072043",
      "title": "Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms",
      "status": "COMPLETED",
      "last_update": "2022-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03588078",
      "title": "Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine",
      "status": "UNKNOWN",
      "last_update": "2020-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FEDRATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05524857",
      "title": "Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)",
      "status": "TERMINATED",
      "last_update": "2024-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FLUMATINIB": {
    "n": 9,
    "n_observational": 4,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01503502",
      "title": "A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-04-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02204644",
      "title": "The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML",
      "status": "COMPLETED",
      "last_update": "2018-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02511340",
      "title": "A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients",
      "status": "UNKNOWN",
      "last_update": "2015-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04677439",
      "title": "Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure",
      "status": "UNKNOWN",
      "last_update": "2022-03-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04933526",
      "title": "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients",
      "status": "UNKNOWN",
      "last_update": "2022-07-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05353205",
      "title": "A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.",
      "status": "UNKNOWN",
      "last_update": "2022-04-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05367765",
      "title": "A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-05-10",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05433532",
      "title": "Study of Azacitidine\uff0cVenetoclax\uff0cand Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients",
      "status": "COMPLETED",
      "last_update": "2024-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06530810",
      "title": "Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ILORASERTIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01110473",
      "title": "ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-11-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IMATINIB": {
    "n": 167,
    "n_observational": 33,
    "n_active": 17,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT01746836",
      "title": "Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03459534",
      "title": "A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04838041",
      "title": "Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04877522",
      "title": "Asciminib Roll-over Study",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004932",
      "title": "STI571 in Treating Patients With Recurrent Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006052",
      "title": "STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006053",
      "title": "STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa",
      "status": "COMPLETED",
      "last_update": "2013-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006343",
      "title": "STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006475",
      "title": "STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis",
      "status": "COMPLETED",
      "last_update": "2013-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00015834",
      "title": "STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00015847",
      "title": "Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00015860",
      "title": "STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022490",
      "title": "Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2016-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025415",
      "title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction",
      "status": "COMPLETED",
      "last_update": "2013-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00038675",
      "title": "Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2022-01-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00039416",
      "title": "Imatinib Mesylate in Treating Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2014-02-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00041990",
      "title": "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)",
      "status": "COMPLETED",
      "last_update": "2007-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00042003",
      "title": "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)",
      "status": "COMPLETED",
      "last_update": "2024-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00042016",
      "title": "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)",
      "status": "COMPLETED",
      "last_update": "2009-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00045422",
      "title": "Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00047502",
      "title": "Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-11-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00050531",
      "title": "High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2016-05-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00053248",
      "title": "Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2012-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054431",
      "title": "Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00066326",
      "title": "Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070499",
      "title": "Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00081926",
      "title": "Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2009-11-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088231",
      "title": "PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP",
      "status": "COMPLETED",
      "last_update": "2012-01-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00093639",
      "title": "Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2013-05-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00100997",
      "title": "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2013-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101660",
      "title": "Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib",
      "status": "COMPLETED",
      "last_update": "2012-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101816",
      "title": "Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2010-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00109707",
      "title": "A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110058",
      "title": "Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00114959",
      "title": "Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2015-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00123474",
      "title": "Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML",
      "status": "COMPLETED",
      "last_update": "2016-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00123487",
      "title": "Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML",
      "status": "COMPLETED",
      "last_update": "2014-11-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00124748",
      "title": "Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)",
      "status": "TERMINATED",
      "last_update": "2012-02-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00146913",
      "title": "AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year",
      "status": "UNKNOWN",
      "last_update": "2007-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171249",
      "title": "An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171899",
      "title": "Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2017-02-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171912",
      "title": "Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes",
      "status": "COMPLETED",
      "last_update": "2017-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00199186",
      "title": "Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "UNKNOWN",
      "last_update": "2007-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00210119",
      "title": "Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response",
      "status": "TERMINATED",
      "last_update": "2021-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00219726",
      "title": "Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2012-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00237120",
      "title": "Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)",
      "status": "COMPLETED",
      "last_update": "2009-11-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244829",
      "title": "Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00258271",
      "title": "Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00264160",
      "title": "Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy",
      "status": "COMPLETED",
      "last_update": "2017-03-06",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00267085",
      "title": "Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease",
      "status": "COMPLETED",
      "last_update": "2012-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00297570",
      "title": "Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy",
      "status": "UNKNOWN",
      "last_update": "2007-10-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00298987",
      "title": "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2010-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00320190",
      "title": "Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib",
      "status": "TERMINATED",
      "last_update": "2013-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324077",
      "title": "Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "WITHDRAWN",
      "last_update": "2016-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00327262",
      "title": "Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase",
      "status": "UNKNOWN",
      "last_update": "2006-06-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00333840",
      "title": "Safety and Efficacy of Imatinib Versus Interferon-\u03b1 Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-10-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00362466",
      "title": "A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy",
      "status": "TERMINATED",
      "last_update": "2009-11-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00363649",
      "title": "Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI",
      "status": "COMPLETED",
      "last_update": "2018-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00384228",
      "title": "A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00390897",
      "title": "Glivec\u00ae (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec\u00ae-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2008-11-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00415857",
      "title": "Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)",
      "status": "TERMINATED",
      "last_update": "2018-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00416884",
      "title": "Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML",
      "status": "TERMINATED",
      "last_update": "2017-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00420043",
      "title": "Effect of Food on Bioavailability of Modified Release Formulations of Imatinib",
      "status": "COMPLETED",
      "last_update": "2016-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00422825",
      "title": "Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib",
      "status": "COMPLETED",
      "last_update": "2016-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00428909",
      "title": "Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2016-04-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00461929",
      "title": "Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib",
      "status": "TERMINATED",
      "last_update": "2009-02-13",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00466726",
      "title": "Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00471497",
      "title": "A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2020-11-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00478985",
      "title": "Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-07-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00481247",
      "title": "A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-02-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00493181",
      "title": "Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients",
      "status": "COMPLETED",
      "last_update": "2012-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00510926",
      "title": "Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2007-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00511303",
      "title": "Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2007-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00538109",
      "title": "An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec\u00ae/Gleevec\u00ae_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2015-12-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00573378",
      "title": "Imatinib or Nilotinib With Pegylated Interferon-\u03b12b in Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2023-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00574873",
      "title": "Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML",
      "status": "COMPLETED",
      "last_update": "2019-01-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00580281",
      "title": "Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors",
      "status": "COMPLETED",
      "last_update": "2013-10-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00594555",
      "title": "A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2008-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00661180",
      "title": "Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec",
      "status": "COMPLETED",
      "last_update": "2014-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00686218",
      "title": "Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00763763",
      "title": "Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive",
      "status": "COMPLETED",
      "last_update": "2011-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00769327",
      "title": "Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00811070",
      "title": "Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias",
      "status": "COMPLETED",
      "last_update": "2016-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00845221",
      "title": "Glivec in Pediatric Chronic Myeloid Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2016-10-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00852566",
      "title": "Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00852709",
      "title": "Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias",
      "status": "TERMINATED",
      "last_update": "2018-02-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00858806",
      "title": "Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy",
      "status": "COMPLETED",
      "last_update": "2014-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00860535",
      "title": "Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)",
      "status": "TERMINATED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00955916",
      "title": "CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)",
      "status": "COMPLETED",
      "last_update": "2014-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00980018",
      "title": "An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment",
      "status": "COMPLETED",
      "last_update": "2021-07-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00982488",
      "title": "Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01030718",
      "title": "Rollover Study of BMS-354825 in Patients With CML and Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2010-12-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01043874",
      "title": "Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response",
      "status": "COMPLETED",
      "last_update": "2016-04-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01066468",
      "title": "Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec\u00ae Indicated Hematological Disorders.",
      "status": "TERMINATED",
      "last_update": "2012-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01114087",
      "title": "Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility",
      "status": "COMPLETED",
      "last_update": "2011-03-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01126892",
      "title": "A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2017-02-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01131325",
      "title": "Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations",
      "status": "TERMINATED",
      "last_update": "2021-05-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01169753",
      "title": "Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients",
      "status": "TERMINATED",
      "last_update": "2015-12-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216085",
      "title": "An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints",
      "status": "COMPLETED",
      "last_update": "2021-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01221376",
      "title": "Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)",
      "status": "UNKNOWN",
      "last_update": "2013-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01227356",
      "title": "A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-10-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01254188",
      "title": "Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients",
      "status": "COMPLETED",
      "last_update": "2016-03-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01270984",
      "title": "Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects",
      "status": "COMPLETED",
      "last_update": "2012-10-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01279473",
      "title": "Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01316250",
      "title": "Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-10-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01343173",
      "title": "Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib",
      "status": "COMPLETED",
      "last_update": "2026-07-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01368523",
      "title": "Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial",
      "status": "COMPLETED",
      "last_update": "2016-11-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01397734",
      "title": "Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2018-09-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01426334",
      "title": "Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate",
      "status": "TERMINATED",
      "last_update": "2014-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01460693",
      "title": "Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2018-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01490775",
      "title": "Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy",
      "status": "TERMINATED",
      "last_update": "2018-08-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01490983",
      "title": "Telemonitoring Study - for Chronic Myeloid Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2018-08-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01503502",
      "title": "A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-04-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01511289",
      "title": "Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients",
      "status": "COMPLETED",
      "last_update": "2016-02-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01602952",
      "title": "Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI",
      "status": "COMPLETED",
      "last_update": "2018-08-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01660906",
      "title": "Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib",
      "status": "COMPLETED",
      "last_update": "2016-11-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01698905",
      "title": "Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)",
      "status": "COMPLETED",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01742299",
      "title": "Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01744665",
      "title": "A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation",
      "status": "COMPLETED",
      "last_update": "2020-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01751919",
      "title": "A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)",
      "status": "COMPLETED",
      "last_update": "2014-10-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01755325",
      "title": "Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+",
      "status": "SUSPENDED",
      "last_update": "2018-04-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01802450",
      "title": "Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "UNKNOWN",
      "last_update": "2015-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01804985",
      "title": "De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2025-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01819389",
      "title": "Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance",
      "status": "COMPLETED",
      "last_update": "2014-01-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914484",
      "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081378",
      "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02086487",
      "title": "Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy",
      "status": "TERMINATED",
      "last_update": "2017-03-07",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115386",
      "title": "Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib",
      "status": "TERMINATED",
      "last_update": "2019-12-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115672",
      "title": "Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2016-08-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02130557",
      "title": "A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02174445",
      "title": "An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response \u2265 4 Log (MR4) at Two Years",
      "status": "TERMINATED",
      "last_update": "2019-12-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02204644",
      "title": "The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML",
      "status": "COMPLETED",
      "last_update": "2018-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02204722",
      "title": "A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients",
      "status": "TERMINATED",
      "last_update": "2018-06-15",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02268370",
      "title": "Treatment-free Remission Accomplished With Dasatinib in Patients With CML",
      "status": "UNKNOWN",
      "last_update": "2019-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02272777",
      "title": "A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02326311",
      "title": "Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients \u226560 Years in Deep Molecular Response",
      "status": "COMPLETED",
      "last_update": "2024-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02352558",
      "title": "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02398825",
      "title": "Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib",
      "status": "TERMINATED",
      "last_update": "2025-01-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02480608",
      "title": "Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)",
      "status": "COMPLETED",
      "last_update": "2015-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02627677",
      "title": "A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02687425",
      "title": "Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2016-02-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02852486",
      "title": "Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02896842",
      "title": "A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML",
      "status": "COMPLETED",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03062436",
      "title": "To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission",
      "status": "UNKNOWN",
      "last_update": "2019-07-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03214718",
      "title": "Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-07-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03239886",
      "title": "Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log",
      "status": "UNKNOWN",
      "last_update": "2018-03-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03515018",
      "title": "Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients",
      "status": "UNKNOWN",
      "last_update": "2018-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03516279",
      "title": "Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03578367",
      "title": "Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610971",
      "title": "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654768",
      "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03722420",
      "title": "Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04006847",
      "title": "Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-07-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04043676",
      "title": "Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2019-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04070443",
      "title": "Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126681",
      "title": "A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04147533",
      "title": "Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626024",
      "title": "Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04677439",
      "title": "Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure",
      "status": "UNKNOWN",
      "last_update": "2022-03-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04883125",
      "title": "Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment",
      "status": "COMPLETED",
      "last_update": "2021-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04933526",
      "title": "The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients",
      "status": "UNKNOWN",
      "last_update": "2022-07-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971226",
      "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05367765",
      "title": "A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-05-10",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05413915",
      "title": "Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML",
      "status": "TERMINATED",
      "last_update": "2026-05-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07022743",
      "title": "Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07158294",
      "title": "Identification of BCR::ABL1 Mutations by Digital PCR in CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493408",
      "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "KW-2449": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00346632",
      "title": "An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2024-05-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MOMELOTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05488548",
      "title": "Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-01-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07071155",
      "title": "Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-03-27",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAVITOCLAX": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04041050",
      "title": "A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAVTEMADLIN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04835584",
      "title": "KRT-232 and TKI Study in Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NILOTINIB": {
    "n": 110,
    "n_observational": 34,
    "n_active": 15,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT01746836",
      "title": "Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04838041",
      "title": "Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04877522",
      "title": "Asciminib Roll-over Study",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06409936",
      "title": "PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML",
      "status": "RECRUITING",
      "last_update": "2025-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00036738",
      "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "COMPLETED",
      "last_update": "2020-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00109707",
      "title": "A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00129740",
      "title": "Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2019-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00264160",
      "title": "Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy",
      "status": "COMPLETED",
      "last_update": "2017-03-06",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00384228",
      "title": "A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00471497",
      "title": "A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2020-11-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00481052",
      "title": "Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2022-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00519090",
      "title": "Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",
      "status": "TERMINATED",
      "last_update": "2011-11-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00573378",
      "title": "Imatinib or Nilotinib With Pegylated Interferon-\u03b12b in Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2023-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00644878",
      "title": "Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib",
      "status": "TERMINATED",
      "last_update": "2021-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00702403",
      "title": "Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML",
      "status": "COMPLETED",
      "last_update": "2017-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00750659",
      "title": "Nilotinib Pre and Post Allogeneic Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2016-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00760877",
      "title": "Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)",
      "status": "COMPLETED",
      "last_update": "2016-11-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00769327",
      "title": "Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00786812",
      "title": "Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2017-02-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00802841",
      "title": "Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib",
      "status": "COMPLETED",
      "last_update": "2015-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00809211",
      "title": "Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00860535",
      "title": "Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)",
      "status": "TERMINATED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00980018",
      "title": "An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment",
      "status": "COMPLETED",
      "last_update": "2021-07-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01043874",
      "title": "Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response",
      "status": "COMPLETED",
      "last_update": "2016-04-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01061177",
      "title": "Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2017-02-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01077544",
      "title": "A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2020-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01126892",
      "title": "A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2017-02-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01131325",
      "title": "Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations",
      "status": "TERMINATED",
      "last_update": "2021-05-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01169753",
      "title": "Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients",
      "status": "TERMINATED",
      "last_update": "2015-12-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01206088",
      "title": "Tasigna in Glivec-resistant or Intolerant Patients in CML",
      "status": "COMPLETED",
      "last_update": "2017-02-28",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207440",
      "title": "Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2021-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01220648",
      "title": "Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2015-05-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01223898",
      "title": "To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib",
      "status": "COMPLETED",
      "last_update": "2020-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01227577",
      "title": "CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib",
      "status": "COMPLETED",
      "last_update": "2016-02-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01254188",
      "title": "Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients",
      "status": "COMPLETED",
      "last_update": "2016-03-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01274351",
      "title": "Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2020-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01275196",
      "title": "Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients",
      "status": "COMPLETED",
      "last_update": "2016-04-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01279473",
      "title": "Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01294618",
      "title": "Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01316250",
      "title": "Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-10-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01368523",
      "title": "Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial",
      "status": "COMPLETED",
      "last_update": "2016-11-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01397734",
      "title": "Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2018-09-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01400074",
      "title": "Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib",
      "status": "UNKNOWN",
      "last_update": "2014-01-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01456676",
      "title": "Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy",
      "status": "COMPLETED",
      "last_update": "2020-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01490775",
      "title": "Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy",
      "status": "TERMINATED",
      "last_update": "2018-08-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01490983",
      "title": "Telemonitoring Study - for Chronic Myeloid Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2018-08-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01535391",
      "title": "Nilotinib in PH+, BCR-, ABL+ CML Patients",
      "status": "COMPLETED",
      "last_update": "2018-08-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01602952",
      "title": "Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI",
      "status": "COMPLETED",
      "last_update": "2018-08-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01605981",
      "title": "Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.",
      "status": "WITHDRAWN",
      "last_update": "2017-04-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01657604",
      "title": "TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study",
      "status": "COMPLETED",
      "last_update": "2023-05-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01667133",
      "title": "A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2022-06-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01670084",
      "title": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2015-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01690065",
      "title": "Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML",
      "status": "UNKNOWN",
      "last_update": "2016-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01698905",
      "title": "Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)",
      "status": "COMPLETED",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01702064",
      "title": "Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients",
      "status": "COMPLETED",
      "last_update": "2021-01-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01735955",
      "title": "Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study",
      "status": "COMPLETED",
      "last_update": "2024-02-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01743989",
      "title": "A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.",
      "status": "COMPLETED",
      "last_update": "2021-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01744665",
      "title": "A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation",
      "status": "COMPLETED",
      "last_update": "2020-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01751425",
      "title": "Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01774630",
      "title": "Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)",
      "status": "COMPLETED",
      "last_update": "2026-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01784068",
      "title": "Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients",
      "status": "COMPLETED",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01804985",
      "title": "De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2025-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01819389",
      "title": "Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance",
      "status": "COMPLETED",
      "last_update": "2014-01-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01844765",
      "title": "Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.",
      "status": "COMPLETED",
      "last_update": "2021-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01856283",
      "title": "Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells",
      "status": "COMPLETED",
      "last_update": "2021-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01866553",
      "title": "Nilotinib Plus Pegylated Interferon-\u03b12b in CML",
      "status": "TERMINATED",
      "last_update": "2018-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914484",
      "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02001818",
      "title": "Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2024-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081378",
      "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02086487",
      "title": "Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy",
      "status": "TERMINATED",
      "last_update": "2017-03-07",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02108951",
      "title": "Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.",
      "status": "TERMINATED",
      "last_update": "2017-10-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115386",
      "title": "Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib",
      "status": "TERMINATED",
      "last_update": "2019-12-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02174445",
      "title": "An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response \u2265 4 Log (MR4) at Two Years",
      "status": "TERMINATED",
      "last_update": "2019-12-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02201459",
      "title": "Nilotinib \u00b1 Peg-IFN for First Line Chronic Phase CML Patients",
      "status": "COMPLETED",
      "last_update": "2025-10-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02225574",
      "title": "An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",
      "status": "TERMINATED",
      "last_update": "2020-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02253277",
      "title": "Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients",
      "status": "COMPLETED",
      "last_update": "2019-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02269267",
      "title": "The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)",
      "status": "COMPLETED",
      "last_update": "2023-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02272777",
      "title": "A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02326311",
      "title": "Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients \u226560 Years in Deep Molecular Response",
      "status": "COMPLETED",
      "last_update": "2024-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02353728",
      "title": "Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy",
      "status": "COMPLETED",
      "last_update": "2022-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02389920",
      "title": "Multicenter, Phase\u2163, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib",
      "status": "UNKNOWN",
      "last_update": "2015-03-17",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02546674",
      "title": "Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.",
      "status": "COMPLETED",
      "last_update": "2022-07-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02602314",
      "title": "Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-01-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02627677",
      "title": "A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02709083",
      "title": "Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2018-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02917720",
      "title": "2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02973711",
      "title": "A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML",
      "status": "WITHDRAWN",
      "last_update": "2021-02-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03079505",
      "title": "Dasatinib Versus Nilotinib for Treatment Na\u00efve Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2019-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03205267",
      "title": "Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients",
      "status": "UNKNOWN",
      "last_update": "2017-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03214718",
      "title": "Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-07-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228303",
      "title": "Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-10-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03332511",
      "title": "Efficacy and Safety of Nilotinib in CML-CP",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03516279",
      "title": "Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03578367",
      "title": "Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610971",
      "title": "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654768",
      "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03874858",
      "title": "A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03906292",
      "title": "Frontline Asciminib Combination in Chronic Phase CML",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03942094",
      "title": "Nilotinib for First-line Newly Diagnosed CML-CP Patients",
      "status": "UNKNOWN",
      "last_update": "2022-03-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04006847",
      "title": "Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-07-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126681",
      "title": "A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04147533",
      "title": "Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04216563",
      "title": "ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor",
      "status": "TERMINATED",
      "last_update": "2026-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578847",
      "title": "A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)",
      "status": "UNKNOWN",
      "last_update": "2020-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626024",
      "title": "Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835584",
      "title": "KRT-232 and TKI Study in Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04971226",
      "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05143840",
      "title": "Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05456191",
      "title": "A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (\u226518 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493408",
      "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NILOTINIB HYDROCHLORIDE": {
    "n": 3,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01746836",
      "title": "Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01670084",
      "title": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2015-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654768",
      "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBATOCLAX": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00438178",
      "title": "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2014-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00933985",
      "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia",
      "status": "TERMINATED",
      "last_update": "2014-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBLIMERSEN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00049192",
      "title": "Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OLVEREMBATINIB": {
    "n": 11,
    "n_observational": 2,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06401603",
      "title": "A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06423911",
      "title": "Study of Olverembatinib (HQP1351) in Patients With CP-CML",
      "status": "RECRUITING",
      "last_update": "2025-06-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06757855",
      "title": "Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML",
      "status": "RECRUITING",
      "last_update": "2025-05-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06817720",
      "title": "Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03882281",
      "title": "Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-01-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03883087",
      "title": "A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation",
      "status": "UNKNOWN",
      "last_update": "2023-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03883100",
      "title": "A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation",
      "status": "UNKNOWN",
      "last_update": "2023-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126681",
      "title": "A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126707",
      "title": "The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans",
      "status": "COMPLETED",
      "last_update": "2021-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05311943",
      "title": "Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.",
      "status": "UNKNOWN",
      "last_update": "2022-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05376852",
      "title": "Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML",
      "status": "UNKNOWN",
      "last_update": "2022-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PACRITINIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06159491",
      "title": "Pacritinib in CMML",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06218628",
      "title": "Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition",
      "status": "RECRUITING",
      "last_update": "2024-05-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07033598",
      "title": "Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02564536",
      "title": "Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)",
      "status": "WITHDRAWN",
      "last_update": "2017-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PONATINIB": {
    "n": 26,
    "n_observational": 17,
    "n_active": 9,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01746836",
      "title": "Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03263572",
      "title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03934372",
      "title": "Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06514534",
      "title": "Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.",
      "status": "RECRUITING",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00660920",
      "title": "Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2018-05-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207440",
      "title": "Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2021-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01424982",
      "title": "Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01570868",
      "title": "Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)",
      "status": "TERMINATED",
      "last_update": "2025-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01650805",
      "title": "Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)",
      "status": "TERMINATED",
      "last_update": "2014-11-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01667133",
      "title": "A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2022-06-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02398825",
      "title": "Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib",
      "status": "TERMINATED",
      "last_update": "2025-01-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02467270",
      "title": "Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses",
      "status": "COMPLETED",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02627677",
      "title": "A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02629692",
      "title": "Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to \u22653 Prior CML Therapies",
      "status": "TERMINATED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03147612",
      "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03576547",
      "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03807479",
      "title": "Study in Patients With Chronic Leukemia",
      "status": "TERMINATED",
      "last_update": "2023-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03895671",
      "title": "PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS",
      "status": "COMPLETED",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04043676",
      "title": "Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2019-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04070443",
      "title": "Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04160546",
      "title": "Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04188405",
      "title": "Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04233346",
      "title": "The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04709731",
      "title": "Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RADOTINIB": {
    "n": 5,
    "n_observational": 2,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03459534",
      "title": "A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01511289",
      "title": "Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients",
      "status": "COMPLETED",
      "last_update": "2016-02-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01602952",
      "title": "Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI",
      "status": "COMPLETED",
      "last_update": "2018-08-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02422719",
      "title": "Radotinib as 3rd or Later Line Therapy in CP-CML",
      "status": "UNKNOWN",
      "last_update": "2016-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03722420",
      "title": "Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REBASTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00827138",
      "title": "Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)",
      "status": "COMPLETED",
      "last_update": "2014-07-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REGORAFENIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RUXOLITINIB": {
    "n": 22,
    "n_observational": 0,
    "n_active": 11,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05488548",
      "title": "Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-01-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07128381",
      "title": "Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07238712",
      "title": "Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor",
      "status": "RECRUITING",
      "last_update": "2025-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07249346",
      "title": "Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00674479",
      "title": "INCB018424 in Patients With Advanced Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01164163",
      "title": "INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",
      "status": "COMPLETED",
      "last_update": "2014-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01702064",
      "title": "Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients",
      "status": "COMPLETED",
      "last_update": "2021-01-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01751425",
      "title": "Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01776723",
      "title": "A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib",
      "status": "COMPLETED",
      "last_update": "2022-09-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914484",
      "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02092324",
      "title": "Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02253277",
      "title": "Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients",
      "status": "COMPLETED",
      "last_update": "2019-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02386800",
      "title": "CINC424A2X01B Rollover Protocol",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02973711",
      "title": "A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML",
      "status": "WITHDRAWN",
      "last_update": "2021-02-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610971",
      "title": "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654768",
      "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03722407",
      "title": "Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04041050",
      "title": "A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05088356",
      "title": "Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VALSPODAR": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00005823",
      "title": "Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2013-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VENETOCLAX": {
    "n": 51,
    "n_observational": 4,
    "n_active": 24,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT02115295",
      "title": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03850574",
      "title": "Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "status": "RECRUITING",
      "last_update": "2025-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04140487",
      "title": "Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04256317",
      "title": "A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)",
      "status": "RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04581512",
      "title": "Study to Evaluate the Safety and Tolerability of EP0042",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04588922",
      "title": "Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04708054",
      "title": "Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05184842",
      "title": "Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05584761",
      "title": "Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML",
      "status": "RECRUITING",
      "last_update": "2022-10-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05807932",
      "title": "Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML",
      "status": "RECRUITING",
      "last_update": "2024-05-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06757855",
      "title": "Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML",
      "status": "RECRUITING",
      "last_update": "2025-05-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06778187",
      "title": "Oral-ATO for TP53-mutated Myeloid Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02265731",
      "title": "Study Evaluating Venetoclax in Subjects With Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-08-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02397720",
      "title": "Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02689440",
      "title": "Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03404193",
      "title": "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome",
      "status": "TERMINATED",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03455517",
      "title": "Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547115",
      "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML",
      "status": "TERMINATED",
      "last_update": "2026-03-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03576547",
      "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03613532",
      "title": "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03844048",
      "title": "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03862157",
      "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03922100",
      "title": "Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML",
      "status": "TERMINATED",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04146038",
      "title": "Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease",
      "status": "COMPLETED",
      "last_update": "2023-05-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04160052",
      "title": "Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome",
      "status": "TERMINATED",
      "last_update": "2026-02-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04188405",
      "title": "Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04372433",
      "title": "IO-202 as Monotherapy and IO-202 Plus Azacitidine \u00b1 Venetoclax in Patients in AML and CMML",
      "status": "COMPLETED",
      "last_update": "2025-02-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04477291",
      "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS",
      "status": "TERMINATED",
      "last_update": "2025-03-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04487106",
      "title": "Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2025-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04512105",
      "title": "Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04550442",
      "title": "Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04553692",
      "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers",
      "status": "TERMINATED",
      "last_update": "2025-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04603001",
      "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04609826",
      "title": "A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",
      "status": "COMPLETED",
      "last_update": "2025-10-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04655755",
      "title": "Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04752163",
      "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04937166",
      "title": "A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-11-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05107856",
      "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05201066",
      "title": "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05209152",
      "title": "AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05428969",
      "title": "A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05433532",
      "title": "Study of Azacitidine\uff0cVenetoclax\uff0cand Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients",
      "status": "COMPLETED",
      "last_update": "2024-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05600894",
      "title": "Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05701215",
      "title": "Venetoclax After TKI to Target Persisting Stem Cells in CML",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05768711",
      "title": "Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06085638",
      "title": "Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2024-03-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563804",
      "title": "A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML",
      "status": "TERMINATED",
      "last_update": "2026-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07082452",
      "title": "A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Na\u00efve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-07-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07604233",
      "title": "Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VODOBATINIB": {
    "n": 1,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02629692",
      "title": "Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to \u22653 Prior CML Therapies",
      "status": "TERMINATED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "XL-228": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00464113",
      "title": "Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2015-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}